+关注
godspeed
暂无个人介绍
IP属地:未知
88
关注
5
粉丝
1
主题
0
勋章
主贴
热门
godspeed
2020-04-25
追加的3000万美元杠杠的。美国已经开始调查谭书记了。
神药无效?瑞德西韦中国试验发生了什么
godspeed
2017-03-09
$Phillips 66(PSX)$ diedie跌跌不休啊。
godspeed
2017-02-28
$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。
godspeed
2017-02-28
$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。
godspeed
2017-01-26
$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?
godspeed
2016-09-21
为什么暴跌?
$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。
为什么暴跌?
godspeed
2016-08-31
$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。
godspeed
2016-08-30
$微博(WB)$ 流通股好少,都是庄家在炒的吧。
godspeed
2016-08-26
$麦当劳(MCD)$ 大盘涨那么多你还跌。
godspeed
2016-08-24
$微博(WB)$ 能做空吗?
godspeed
2016-08-08
$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"325321245465411","uuid":"325321245465411","gmtCreate":1468327830328,"gmtModify":1468328036052,"name":"godspeed","pinyin":"godspeed","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":88,"tweetSize":11,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":15,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":925356024,"gmtCreate":1587803919968,"gmtModify":1704365646969,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","listText":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","text":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925356024","repostId":"1162855781","repostType":2,"repost":{"id":"1162855781","kind":"news","weMediaInfo":{"introduction":"华尔街见闻出品,专注于美股市场。为您提供最重要的资讯数据,最全面的市场动态和最深刻的解读分析。","home_visible":1,"media_name":"见闻IPO","id":"1083533104","head_image":"https://static.tigerbbs.com/0717bf7b1e5642e9827aeffbf11eb9ad"},"pubTimestamp":1587690961,"share":"https://www.laohu8.com/m/news/1162855781?lang=&edition=full","pubTime":"2020-04-24 09:16","market":"us","language":"zh","title":"神药无效?瑞德西韦中国试验发生了什么","url":"https://stock-news.laohu8.com/highlight/detail?id=1162855781","media":"见闻IPO","summary":"导读:WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药","content":"<blockquote><b><i><span>导读:</span></i></b><i><span>WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。</span></i></blockquote><p><span>一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。</span></p><p><span>受此影响,该药物研制公司<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。</span></p><p><span><b>01、发生了什么?</b></span></p><p><span>在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。</span></p><p><span>尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。</span></p><p><span>STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。</span></p><p><span>结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。</span></p><p><span>最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。</span></p><p><span>因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:</span></p><blockquote><p><span>在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。</span></p></blockquote><p><span>瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。</span></p><p><span>但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。</span></p><p><span>在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。</span></p><p><img src=\"https://static.tigerbbs.com/6905c757f3a3863d87dc96981c912355\"></p><p><span><b>02、吉利德坚称“瑞德西韦可能有帮助”</b></span></p><p><span>因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。</span></p><p><span>WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。</span></p><p><span>吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。</span></p><p><span>吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。</span></p><p><span>吉利德公告称:</span></p><blockquote><p><span>我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。</span></p><p><span>该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。</span></p><p><span>重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。</span></p><p><span>所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。</span></p><p><span>我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。</span></p><p><span>当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。</span></p><p><span>这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。</span></p></blockquote><p><span><b>03、分析师泼冷水</b></span></p><p><span>在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。</span></p><p><span>Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。</span></p><p><span>也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>神药无效?瑞德西韦中国试验发生了什么</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n神药无效?瑞德西韦中国试验发生了什么\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083533104\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/0717bf7b1e5642e9827aeffbf11eb9ad);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">见闻IPO </p>\n<p class=\"h-time\">2020-04-24 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote><b><i><span>导读:</span></i></b><i><span>WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。</span></i></blockquote><p><span>一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。</span></p><p><span>受此影响,该药物研制公司<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。</span></p><p><span><b>01、发生了什么?</b></span></p><p><span>在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。</span></p><p><span>尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。</span></p><p><span>STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。</span></p><p><span>结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。</span></p><p><span>最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。</span></p><p><span>因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:</span></p><blockquote><p><span>在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。</span></p></blockquote><p><span>瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。</span></p><p><span>但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。</span></p><p><span>在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。</span></p><p><img src=\"https://static.tigerbbs.com/6905c757f3a3863d87dc96981c912355\"></p><p><span><b>02、吉利德坚称“瑞德西韦可能有帮助”</b></span></p><p><span>因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。</span></p><p><span>WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。</span></p><p><span>吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。</span></p><p><span>吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。</span></p><p><span>吉利德公告称:</span></p><blockquote><p><span>我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。</span></p><p><span>该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。</span></p><p><span>重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。</span></p><p><span>所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。</span></p><p><span>我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。</span></p><p><span>当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。</span></p><p><span>这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。</span></p></blockquote><p><span><b>03、分析师泼冷水</b></span></p><p><span>在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。</span></p><p><span>Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。</span></p><p><span>也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。</span></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bafe8d3dd529f9fbd0f2ab811782b48a","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162855781","content_text":"导读:WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。受此影响,该药物研制公司吉利德科学股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。01、发生了什么?在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。02、吉利德坚称“瑞德西韦可能有帮助”因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。吉利德公告称:我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。03、分析师泼冷水在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":48173,"gmtCreate":1489070221890,"gmtModify":1704875537748,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$Phillips 66(PSX)$ diedie跌跌不休啊。","listText":"$Phillips 66(PSX)$ diedie跌跌不休啊。","text":"$Phillips 66(PSX)$ diedie跌跌不休啊。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/48173","isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"93756287018851","authorId":"93756287018851","name":"凛冬将至","avatar":"https://static.laohu8.com/d2a98d2e19873b1e96274cc0762e092a","crmLevel":1,"crmLevelSwitch":0,"idStr":"93756287018851","authorIdStr":"93756287018851"},"content":"这几天估计还得跌。不出意外的话明天油井数量还会增加","text":"这几天估计还得跌。不出意外的话明天油井数量还会增加","html":"这几天估计还得跌。不出意外的话明天油井数量还会增加"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":46352,"gmtCreate":1488217311002,"gmtModify":1704875308610,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","listText":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","text":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/46352","isVote":1,"tweetType":1,"viewCount":2092,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3432847893156433","authorId":"3432847893156433","name":"3bd5d40b","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"3432847893156433","authorIdStr":"3432847893156433"},"content":"坚定看空微博","text":"坚定看空微博","html":"坚定看空微博"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":46341,"gmtCreate":1488213779303,"gmtModify":1704875307566,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","listText":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","text":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/46341","isVote":1,"tweetType":1,"viewCount":2221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":42707,"gmtCreate":1485437127354,"gmtModify":1704874837944,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","listText":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","text":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/42707","isVote":1,"tweetType":1,"viewCount":1955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":28953,"gmtCreate":1474390836203,"gmtModify":1704873098992,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"title":"为什么暴跌?","htmlText":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","listText":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","text":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/28953","isVote":1,"tweetType":1,"viewCount":2525,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"20727972514030","authorId":"20727972514030","name":"Tony特别帅","avatar":"https://static.tigerbbs.com/61f671464b0bc8103579e8d0e2197c48","crmLevel":1,"crmLevelSwitch":0,"idStr":"20727972514030","authorIdStr":"20727972514030"},"content":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。","text":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。","html":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":26925,"gmtCreate":1472652042716,"gmtModify":1704872842008,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","listText":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","text":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/26925","isVote":1,"tweetType":1,"viewCount":3361,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"279458735143104","authorId":"279458735143104","name":"T20211211759","avatar":"https://static.tigerbbs.com/53b1598f277200f048ae4a34b47fe629","crmLevel":2,"crmLevelSwitch":0,"idStr":"279458735143104","authorIdStr":"279458735143104"},"content":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾","text":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾","html":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":26772,"gmtCreate":1472565968075,"gmtModify":1704872822300,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","listText":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","text":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/26772","isVote":1,"tweetType":1,"viewCount":1384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":26433,"gmtCreate":1472222798888,"gmtModify":1704872779634,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","listText":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","text":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/26433","isVote":1,"tweetType":1,"viewCount":1480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":25919,"gmtCreate":1472004159599,"gmtModify":1704872711683,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 能做空吗?","listText":"$微博(WB)$ 能做空吗?","text":"$微博(WB)$ 能做空吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/25919","isVote":1,"tweetType":1,"viewCount":1502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":23556,"gmtCreate":1470669292545,"gmtModify":1704872406464,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","listText":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","text":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/23556","isVote":1,"tweetType":1,"viewCount":709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":26925,"gmtCreate":1472652042716,"gmtModify":1704872842008,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","listText":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","text":"$微博(WB)$ 做空后,我挂了限价单45.5,刚才跌到45.2了怎么没自动成交。后来挂了市价单平仓,实际上成交了,结果还是显示持仓,我又按市价平了一次仓,尼玛的变成做多了。还好有回涨赶快卖掉 ,这软件太不靠谱了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/26925","isVote":1,"tweetType":1,"viewCount":3361,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"279458735143104","authorId":"279458735143104","name":"T20211211759","avatar":"https://static.tigerbbs.com/53b1598f277200f048ae4a34b47fe629","crmLevel":2,"crmLevelSwitch":0,"idStr":"279458735143104","authorIdStr":"279458735143104"},"content":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾","text":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾","html":"跟你一样的情况。我他妈上次本来卖股,始终卖不掉然后就操作了三次,做空2次,被这垃圾软件坑了4万多..程序员不知道控制幂等,垃圾"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":28953,"gmtCreate":1474390836203,"gmtModify":1704873098992,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"title":"为什么暴跌?","htmlText":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","listText":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","text":"$莱纳建筑公司(LEN)$ 美国第二大房屋建筑者Lennar公司季度利润及营收超出预期,这是连续第三季,公司以更高的价格出售了更多的房子,公司订单上涨8.1%。","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/28953","isVote":1,"tweetType":1,"viewCount":2525,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"20727972514030","authorId":"20727972514030","name":"Tony特别帅","avatar":"https://static.tigerbbs.com/61f671464b0bc8103579e8d0e2197c48","crmLevel":1,"crmLevelSwitch":0,"idStr":"20727972514030","authorIdStr":"20727972514030"},"content":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。","text":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。","html":"似乎是周二公布房屋建筑报告的问题吧?有些公司预期不会按照财报走,比如金矿公司财报好但是金价下跌财报股价也是跌的。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":25919,"gmtCreate":1472004159599,"gmtModify":1704872711683,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 能做空吗?","listText":"$微博(WB)$ 能做空吗?","text":"$微博(WB)$ 能做空吗?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/25919","isVote":1,"tweetType":1,"viewCount":1502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":46341,"gmtCreate":1488213779303,"gmtModify":1704875307566,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","listText":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","text":"$阿里巴巴(BABA)$ 传言蚂蚁金服、众安在线保险、奇虎360等公司将获得中国证监会的上市捷径。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/46341","isVote":1,"tweetType":1,"viewCount":2221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":42707,"gmtCreate":1485437127354,"gmtModify":1704874837944,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","listText":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","text":"$强生(JNJ)$ 为什么昨晚我挂$114竟然会成交?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/42707","isVote":1,"tweetType":1,"viewCount":1955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":48173,"gmtCreate":1489070221890,"gmtModify":1704875537748,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$Phillips 66(PSX)$ diedie跌跌不休啊。","listText":"$Phillips 66(PSX)$ diedie跌跌不休啊。","text":"$Phillips 66(PSX)$ diedie跌跌不休啊。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/48173","isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"93756287018851","authorId":"93756287018851","name":"凛冬将至","avatar":"https://static.laohu8.com/d2a98d2e19873b1e96274cc0762e092a","crmLevel":1,"crmLevelSwitch":0,"idStr":"93756287018851","authorIdStr":"93756287018851"},"content":"这几天估计还得跌。不出意外的话明天油井数量还会增加","text":"这几天估计还得跌。不出意外的话明天油井数量还会增加","html":"这几天估计还得跌。不出意外的话明天油井数量还会增加"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":46352,"gmtCreate":1488217311002,"gmtModify":1704875308610,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","listText":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","text":"$微博(WB)$ 截至2016年底,微博月活跃用户全年净增长7700万,增至3.13亿,移动端占比达到90%。这数据靠谱吗?40岁以上人口比例有多少?还有12岁以下的人口有多少?所有13岁到39岁的中国人都是微博活跃用户?微信我还信,毕竟70多岁的农村老人都在用。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/46352","isVote":1,"tweetType":1,"viewCount":2092,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3432847893156433","authorId":"3432847893156433","name":"3bd5d40b","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"3432847893156433","authorIdStr":"3432847893156433"},"content":"坚定看空微博","text":"坚定看空微博","html":"坚定看空微博"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":26433,"gmtCreate":1472222798888,"gmtModify":1704872779634,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","listText":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","text":"$麦当劳(MCD)$ 大盘涨那么多你还跌。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/26433","isVote":1,"tweetType":1,"viewCount":1480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":26772,"gmtCreate":1472565968075,"gmtModify":1704872822300,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","listText":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","text":"$微博(WB)$ 流通股好少,都是庄家在炒的吧。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/26772","isVote":1,"tweetType":1,"viewCount":1384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":23556,"gmtCreate":1470669292545,"gmtModify":1704872406464,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","listText":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","text":"$SPDR黄金ETF(GLD)$ 为什么巴里克和其他金矿都涨了那么多,就这个不涨?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/23556","isVote":1,"tweetType":1,"viewCount":709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":925356024,"gmtCreate":1587803919968,"gmtModify":1704365646969,"author":{"id":"325321245465411","authorId":"325321245465411","name":"godspeed","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"325321245465411","authorIdStr":"325321245465411"},"themes":[],"htmlText":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","listText":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","text":"追加的3000万美元杠杠的。美国已经开始调查谭书记了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/925356024","repostId":"1162855781","repostType":2,"repost":{"id":"1162855781","kind":"news","weMediaInfo":{"introduction":"华尔街见闻出品,专注于美股市场。为您提供最重要的资讯数据,最全面的市场动态和最深刻的解读分析。","home_visible":1,"media_name":"见闻IPO","id":"1083533104","head_image":"https://static.tigerbbs.com/0717bf7b1e5642e9827aeffbf11eb9ad"},"pubTimestamp":1587690961,"share":"https://www.laohu8.com/m/news/1162855781?lang=&edition=full","pubTime":"2020-04-24 09:16","market":"us","language":"zh","title":"神药无效?瑞德西韦中国试验发生了什么","url":"https://stock-news.laohu8.com/highlight/detail?id=1162855781","media":"见闻IPO","summary":"导读:WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药","content":"<blockquote><b><i><span>导读:</span></i></b><i><span>WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。</span></i></blockquote><p><span>一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。</span></p><p><span>受此影响,该药物研制公司<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。</span></p><p><span><b>01、发生了什么?</b></span></p><p><span>在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。</span></p><p><span>尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。</span></p><p><span>STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。</span></p><p><span>结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。</span></p><p><span>最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。</span></p><p><span>因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:</span></p><blockquote><p><span>在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。</span></p></blockquote><p><span>瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。</span></p><p><span>但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。</span></p><p><span>在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。</span></p><p><img src=\"https://static.tigerbbs.com/6905c757f3a3863d87dc96981c912355\"></p><p><span><b>02、吉利德坚称“瑞德西韦可能有帮助”</b></span></p><p><span>因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。</span></p><p><span>WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。</span></p><p><span>吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。</span></p><p><span>吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。</span></p><p><span>吉利德公告称:</span></p><blockquote><p><span>我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。</span></p><p><span>该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。</span></p><p><span>重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。</span></p><p><span>所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。</span></p><p><span>我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。</span></p><p><span>当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。</span></p><p><span>这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。</span></p></blockquote><p><span><b>03、分析师泼冷水</b></span></p><p><span>在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。</span></p><p><span>Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。</span></p><p><span>也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>神药无效?瑞德西韦中国试验发生了什么</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n神药无效?瑞德西韦中国试验发生了什么\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083533104\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/0717bf7b1e5642e9827aeffbf11eb9ad);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">见闻IPO </p>\n<p class=\"h-time\">2020-04-24 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote><b><i><span>导读:</span></i></b><i><span>WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。</span></i></blockquote><p><span>一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。</span></p><p><span>受此影响,该药物研制公司<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。</span></p><p><span><b>01、发生了什么?</b></span></p><p><span>在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。</span></p><p><span>尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。</span></p><p><span>STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。</span></p><p><span>结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。</span></p><p><span>最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。</span></p><p><span>因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:</span></p><blockquote><p><span>在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。</span></p></blockquote><p><span>瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。</span></p><p><span>但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。</span></p><p><span>在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。</span></p><p><img src=\"https://static.tigerbbs.com/6905c757f3a3863d87dc96981c912355\"></p><p><span><b>02、吉利德坚称“瑞德西韦可能有帮助”</b></span></p><p><span>因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。</span></p><p><span>WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。</span></p><p><span>吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。</span></p><p><span>吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。</span></p><p><span>吉利德公告称:</span></p><blockquote><p><span>我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。</span></p><p><span>该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。</span></p><p><span>重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。</span></p><p><span>所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。</span></p><p><span>我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。</span></p><p><span>当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。</span></p><p><span>这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。</span></p></blockquote><p><span><b>03、分析师泼冷水</b></span></p><p><span>在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。</span></p><p><span>Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。</span></p><p><span>也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。</span></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bafe8d3dd529f9fbd0f2ab811782b48a","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162855781","content_text":"导读:WHO网站意外发布并迅速删除的报告显示,瑞德西韦并未改善病情,服药后患者血液中的病毒也未减少。而且服药的患者中,有些人还出现明显副作用。一篇意外发布的研究论文摘要,重创了外界对新冠肺炎治疗“神药”瑞德西韦的期待。受此影响,该药物研制公司吉利德科学股价跳水。投行人士表示,这一研究不仅没有显示出临床疗效,甚至没有抗病毒作用,它接近“最糟糕的情形”,应当让人冷静下来。01、发生了什么?在外界焦急等待吉利德在中国进行的临床试验结果之际,周四一份发布于世界卫生组织(WHO)的研究报告摘要,意外提前透露了数据。尽管这一报告很快就被撤下来,但在消失之前被媒体获取,其中数据也被公布了出来。STAT公布的报告摘要显示,在针对237名中国病患的试验中,研究人员给其中158人服用瑞德西韦,另外79人未服用此药。结果显示,瑞德西韦并未改善病患的病情,服药后患者血液中的病毒并未减少。而且服药的患者中,有些人还出现了明显的副作用。最终数据显示,13.9%使用了瑞德西韦的患者死亡。而相比之下,对照组接受标准治疗过程中患者死亡的比例为12.8%。上述报告摘要提到,在数据上,这二者比例并无太大差别。因此报告表示,瑞德西韦与患者临床状况改善没有关系。其中写道:在这项提前终止的针对新冠肺炎重症患者的研究中,瑞德西韦与临床以及病毒感染情况改善没有关系。瑞德西韦在中国的两项新冠肺炎研究于2月初启动,分别针对轻型、普通型患者(NCT04252664)以及重型患者(NCT04257656),各自拟入组308和453例患者。但在上周,瑞德西韦针对重症新冠肺炎患者的临床试验由于入组率低,已经终止研究。在上述结果发布后,吉利德股价跳水,日内跌超6%后一度暂停交易。恢复交易后,跌幅曾略有收窄,但随后跌幅再度扩大,一度跌超8%,创3月16日以来最大盘中跌幅。截至收盘,吉利德跌幅收窄至4.34%,报77.78美元。02、吉利德坚称“瑞德西韦可能有帮助”因为这一报告发布引发的巨大反响,WHO随后发公告称,吉利德科学瑞德西韦药物临床研究报告的作者们向WHO提供了文件草稿,无意间被发布到WHO网站上,留意到这一失误时就迅速删除了相关信息。WHO将于4月24日发布合作计划,以促进研发、生产和使用安全与有效的技术,以便阻止、隔离、并治疗新冠肺炎病毒。吉利德科学也表示,上述提前在WHO发布的文章中有对研究的不适当表述。因为录用受试者少,研究很早就终止了,所以不足以在统计学上得出有意义的结论。吉利德称,研究的结果是不确定的,但数据显示的趋势暗示,瑞德西韦可能有帮助,特别是对那些患病早期就得到诊治的病人。吉利德公告称:我们对世界卫生组织过早发布有关该项研究的信息感到遗憾。相关公告随后已被删除。该项研究的调查人员没有提供公布结果的许可。而且,我们认为该公告包含对该项研究的不适当特征描述。重要的是,由于该项研究因参与率低而提前终止,因此无法得出具有统计学意义的结论。所以,研究结果尚无定论,尽管数据趋势表明瑞德西韦可能有益,尤其是早期患者身上。我们获悉已有数据已被提交进行同行评审发表,相关报告将在不久的将来提供该项研究的更详细信息。当前有多个第三阶段研究正在进行,旨在提供确定瑞德西韦用作COVID-19治疗药物的可能性所需的更多数据。这些研究将有助于发现使用瑞德西韦的治疗对象、治疗时机和治疗周期。这些研究有的已经招满试验对象进行初步分析,有的有望在近期招满试验对象。03、分析师泼冷水在看到这一结果后,投行Baird评论称,瑞德西韦药品针对新冠肺炎病毒的研究结果“应当让人冷静下来”。Baird分析师Brian Skorney发布报告称,瑞德西韦在针对新冠肺炎重症患者的临床试验中未能显示出疗效,这接近“最糟糕的情形,因为不仅没有显示出临床疗效,甚至没有抗病毒作用”。不过他认为,最终一种有针对性的抗病毒方法将有效治疗该疾病。也有分析师相对谨慎,另一机构Suntrust表示,从瑞德西韦用于治疗新冠肺炎病毒的有关报告中很难得出太多结论,瑞德西韦在减轻患者症状方面可能仍然有用,“除非我们看到重症对照研究的数据,否则难以深入研究”。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}